Dova Pharmaceuticals (NASDAQ:DOVA) released its earnings results on Thursday. The company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.12, Fidelity Earnings reports. The firm had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $2.66 million.

Dova Pharmaceuticals stock traded down $2.41 during mid-day trading on Friday, hitting $16.89. The company had a trading volume of 647,924 shares, compared to its average volume of 144,409. The firm has a market capitalization of $527.66 million, a P/E ratio of -12.06 and a beta of 0.87. Dova Pharmaceuticals has a 1 year low of $16.63 and a 1 year high of $37.00. The company has a quick ratio of 13.14, a current ratio of 13.19 and a debt-to-equity ratio of 0.17.

A number of analysts recently weighed in on the stock. BidaskClub upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 31st. Raymond James assumed coverage on shares of Dova Pharmaceuticals in a research note on Wednesday, August 29th. They set an “outperform” rating and a $44.00 target price on the stock. Leerink Swann cut their target price on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 4th. Jefferies Financial Group restated a “buy” rating and set a $40.00 target price on shares of Dova Pharmaceuticals in a research note on Sunday, July 15th. Finally, Zacks Investment Research lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $33.20.

In related news, CEO Alex Sapir purchased 21,700 shares of the company’s stock in a transaction on Tuesday, August 14th. The shares were bought at an average cost of $22.83 per share, for a total transaction of $495,411.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 55.50% of the company’s stock.

A hedge fund recently raised its stake in Dova Pharmaceuticals stock. Bank of New York Mellon Corp grew its position in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 196.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,374 shares of the company’s stock after acquiring an additional 30,750 shares during the quarter. Bank of New York Mellon Corp owned about 0.16% of Dova Pharmaceuticals worth $1,387,000 at the end of the most recent reporting period. 36.64% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Dova Pharmaceuticals (DOVA) Posts Earnings Results, Beats Expectations By $0.12 EPS” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Featured Story: Capital Gains

Earnings History for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with's FREE daily email newsletter.